NASDAQ:ANIK Anika Therapeutics (ANIK) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free ANIK Stock Alerts $25.58 -0.32 (-1.24%) (As of 04:15 PM ET) Add Compare Share Share Today's Range$25.48▼$25.8050-Day Range$24.21▼$26.4252-Week Range$16.54▼$28.13Volume48,024 shsAverage Volume79,540 shsMarket Capitalization$379.86 millionP/E RatioN/ADividend YieldN/APrice Target$29.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Anika Therapeutics alerts: Email Address Anika Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside15.5% Upside$29.50 Price TargetShort InterestBearish5.73% of Float Sold ShortDividend StrengthN/ASustainability-2.12Upright™ Environmental ScoreNews Sentiment0.44Based on 5 Articles This WeekInsider TradingN/AProj. Earnings Growth20.54%From $1.12 to $1.35 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.24 out of 5 starsMedical Sector323rd out of 907 stocksSurgical & Medical Instruments Industry39th out of 96 stocks 2.3 Analyst's Opinion Consensus RatingAnika Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAnika Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.73% of the float of Anika Therapeutics has been sold short.Short Interest Ratio / Days to CoverAnika Therapeutics has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Anika Therapeutics has recently increased by 5.28%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnika Therapeutics does not currently pay a dividend.Dividend GrowthAnika Therapeutics does not have a long track record of dividend growth. Previous Next 3.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAnika Therapeutics has received a 44.00% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Synthetic bone grafts", "Medical splints", and "Medical screws" products. See details.Environmental SustainabilityThe Environmental Impact score for Anika Therapeutics is -2.12. Previous Next 1.9 News and Social Media Coverage News SentimentAnika Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Anika Therapeutics this week, compared to 1 article on an average week.MarketBeat FollowsOnly 2 people have added Anika Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anika Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.85% of the stock of Anika Therapeutics is held by insiders.Percentage Held by Institutions91.53% of the stock of Anika Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Anika Therapeutics are expected to grow by 20.54% in the coming year, from $1.12 to $1.35 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anika Therapeutics is -4.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anika Therapeutics is -4.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioAnika Therapeutics has a PEG Ratio of 2.30. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioAnika Therapeutics has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Anika Therapeutics Stock (NASDAQ:ANIK)Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.Read More ANIK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANIK Stock News HeadlinesApril 25, 2024 | finance.yahoo.comAnika Therapeutics (NASDAQ:ANIK) shareholders have endured a 37% loss from investing in the stock three years agoApril 18, 2024 | finance.yahoo.comAnika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024April 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 18, 2024 | globenewswire.comAnika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024April 2, 2024 | globenewswire.comAnika to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMarch 28, 2024 | msn.comViking Therapeutics stock jumps more than 15% on promising weight loss pill dataMarch 16, 2024 | finance.yahoo.comAnika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | markets.businessinsider.comAnika Therapeutics: Strong Q4 Performance and Upbeat FY2024 Outlook Justify Buy Rating and Raised Price TargetApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.March 14, 2024 | finanznachrichten.deAnika Therapeutics Inc.: Anika Reports Fourth Quarter and Year-End 2023 Financial ResultsMarch 14, 2024 | marketwatch.comAnika Therapeutics to Cut Workforce by 9% in Push for ProfitabilityMarch 13, 2024 | globenewswire.comAnika Reports Fourth Quarter and Year-End 2023 Financial ResultsMarch 12, 2024 | msn.comAnika Therapeutics Q4 2023 Earnings PreviewMarch 12, 2024 | seekingalpha.comADC Therapeutics Q4 Earnings PreviewMarch 12, 2024 | benzinga.comEarnings Outlook For Anika TherapeuticsMarch 8, 2024 | globenewswire.comAnika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 8, 2024 | reuters.comEurope waits on ECB as BOJ lights up the yenMarch 7, 2024 | finance.yahoo.comFifth Annual MedExecWomen Conference in April to Discuss This Year’s Top Opportunities in MedtechMarch 7, 2024 | msn.comActivist investor Caligan discloses 9.7% stake in Anika, nominates two director candidatesMarch 1, 2024 | finance.yahoo.comViscosupplementation Market to Reach US$ 7.81 Billion by 2030: A Comprehensive Analysis of Industry Trends, Growth Drivers, and Market ShareFebruary 27, 2024 | globenewswire.comAnika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024February 21, 2024 | finance.yahoo.comAnika Therapeutics Inc (AKP.BE)February 15, 2024 | finance.yahoo.comStoke Therapeutics, Inc. (STOK) Stock Jumps 25.5%: Will It Continue to Soar?February 6, 2024 | finance.yahoo.comPixelgen Technologies and Australian Biosearch Announce Distribution AgreementFebruary 6, 2024 | ca.finance.yahoo.comAnika Therapeutics, Inc. (ANIK)January 22, 2024 | finance.yahoo.comViscosupplementation Market Size Worth USD 10.51 Billion in 2032 | Emergen ResearchJanuary 18, 2024 | finance.yahoo.comIs There An Opportunity With Anika Therapeutics, Inc.'s (NASDAQ:ANIK) 50% Undervaluation?See More Headlines Receive ANIK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today4/25/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies Current SymbolNASDAQ:ANIK CUSIP03525510 CIK898437 Webwww.anikatherapeutics.com Phone(781) 457-9000Fax781-305-9720Employees357Year Founded1992Price Target and Rating Average Stock Price Target$29.50 High Stock Price Target$37.00 Low Stock Price Target$22.00 Potential Upside/Downside+13.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($5.65) Trailing P/E RatioN/A Forward P/E Ratio23.13 P/E Growth2.32Net Income$-82,670,000.00 Net Margins-49.60% Pretax Margin-51.20% Return on Equity-2.10% Return on Assets-1.71% Debt Debt-to-Equity RatioN/A Current Ratio5.26 Quick Ratio3.76 Sales & Book Value Annual Sales$166.66 million Price / Sales2.31 Cash Flow$4.91 per share Price / Cash Flow5.27 Book Value$14.50 per share Price / Book1.79Miscellaneous Outstanding Shares14,850,000Free Float13,981,000Market Cap$384.62 million OptionableOptionable Beta0.76 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Cheryl Renee Blanchard Ph.D. (Age 60)President, CEO & Director Comp: $1.31MMr. Michael L. Levitz (Age 50)Executive VP, CFO & Treasurer Comp: $710.6kMr. David Colleran J.D. (Age 52)Executive VP, General Counsel & Corporate Secretary Comp: $664.54kMs. Anne Nunes (Age 55)Senior VP & COO Mr. Ian W. McLeodVP & Chief Accounting OfficerMr. Mark Namaroff (Age 61)Executive Director of Investor Relations & Corporate Communications Mr. James ChaseSenior Vice President of International Sales & MarketingMr. Ben JosephVice President of Commercial & Corporate DevelopmentMs. Lisa FunicielloVice President of Human ResourcesMore ExecutivesKey CompetitorsOraSure TechnologiesNASDAQ:OSURCerusNASDAQ:CERSUtah Medical ProductsNASDAQ:UTMDAtrionNASDAQ:ATRISurmodicsNASDAQ:SRDXView All CompetitorsInstitutional OwnershipAllspring Global Investments Holdings LLCBought 14,259 shares on 4/18/2024Ownership: 0.440%Fisher Asset Management LLCSold 2,105 shares on 3/5/2024Ownership: 0.264%Trigran Investments Inc.Sold 77,965 shares on 2/14/2024Ownership: 14.611%Invenomic Capital Management LPBought 116,679 shares on 2/14/2024Ownership: 1.437%Tower Research Capital LLC TRCBought 1,947 shares on 2/13/2024Ownership: 0.021%View All Institutional Transactions ANIK Stock Analysis - Frequently Asked Questions Should I buy or sell Anika Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ANIK shares. View ANIK analyst ratings or view top-rated stocks. What is Anika Therapeutics' stock price target for 2024? 2 Wall Street analysts have issued 12 month target prices for Anika Therapeutics' stock. Their ANIK share price targets range from $22.00 to $37.00. On average, they anticipate the company's share price to reach $29.50 in the next year. This suggests a possible upside of 15.5% from the stock's current price. View analysts price targets for ANIK or view top-rated stocks among Wall Street analysts. How have ANIK shares performed in 2024? Anika Therapeutics' stock was trading at $22.66 at the start of the year. Since then, ANIK stock has increased by 12.8% and is now trading at $25.55. View the best growth stocks for 2024 here. Are investors shorting Anika Therapeutics? Anika Therapeutics saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 811,100 shares, an increase of 5.3% from the March 31st total of 770,400 shares. Based on an average daily trading volume, of 81,800 shares, the days-to-cover ratio is presently 9.9 days. Approximately 5.7% of the company's shares are sold short. View Anika Therapeutics' Short Interest. When is Anika Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our ANIK earnings forecast. How can I listen to Anika Therapeutics' earnings call? Anika Therapeutics will be holding an earnings conference call on Wednesday, May 8th at 5:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Anika Therapeutics' earnings last quarter? Anika Therapeutics, Inc. (NASDAQ:ANIK) issued its earnings results on Wednesday, March, 13th. The biotechnology company reported $0.05 earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.20. The biotechnology company had revenue of $42.97 million for the quarter, compared to analysts' expectations of $41.51 million. Anika Therapeutics had a negative trailing twelve-month return on equity of 2.10% and a negative net margin of 49.60%. What ETF holds Anika Therapeutics' stock? Invesco Nasdaq Future Gen 200 ETF holds 1,676 shares of ANIK stock, representing 0.54% of its portfolio. What guidance has Anika Therapeutics issued on next quarter's earnings? Anika Therapeutics updated its FY 2024 earnings guidance on Wednesday, March, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $168.0 million-$173.0 million, compared to the consensus revenue estimate of $179.4 million. What other stocks do shareholders of Anika Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND). Who are Anika Therapeutics' major shareholders? Anika Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.44%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, Jeffery S Thompson, John B Henneman III, Michael L Levitz and Raymond J Land. View institutional ownership trends. How do I buy shares of Anika Therapeutics? Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ANIK) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anika Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
